[ Follow Ups ] [ Post Followup ] [ The Islet Foundation Message Forum ] [ FAQ ]
Posted by Alexander on 15:01:01 2004/08/03
In Reply to: Potential Cure of Typr 1?? posted by DWK
Well, "potential cure" may be a bit strong -- The Institute for Therapeutic Discovery website (www.titd.org) states " ... early anecdotal human experience indicates that diabetes may actually be reversible, meaning that the patient may be able to stop medical treatment."
The Institute appears to be trying to raise funds to establish an in house lab to begin some of their own basic science animal studies using preliminary results associated with a recently issued patent -- which appears to be owned by a for profit company. It is not clear (based on limited PubMed search) if results were published in peer reviewed journal.
According to the United States Patent Office (www.uspto.gov/patft/index.html) search -- John McMichael's US Patent 6,713,058 (filed 8/19/02; issued 3/30/04; assigned to Milkhaus Laboratory, Inc., Delanson, NY) Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies -- and more his recent submissions -- provide the only the following somewhat limuted and dated evidence (human patients -- prior to 8/19/02) with no more recent results or peer reviewed publications --
Example X
According to this example, a 45 year old female diagnosed with insulin-dependent diabetes was treated with low level antibodies (Abs directed against combination of GAD-65 and GAD-67). The subject was determined to have a hemoglobin A1C level of 11%, which is typically at a level of 4-6% in non-diabetic individuals. The subject experienced neuropathy characterized by numbness and poor circulation as determined by the subject in response to a tuning fork test. The subject underwent antibody therapy by sublingual administration, via drops, twice daily of one dose of anti-GAD (8.times.10.sup.-4 mg) and anti-insulin antibodies (4.times.10.sup.-4 mg). The antibodies used in this example are the same as that used above in Example I. The subject was tested for hemoglobin A1C levels after 2 weeks of therapy and the levels were reduced to 7%. The subject was free from any other therapies during the low level antibody therapy. After one week the subject experienced a disappearance of neuropathy in the subject's lower extremities. The low level antibody treatment was stopped and the subject's previously experienced neuropathy returned after approximately one week.
Example XI
According to this example, a 42 year old female with a 20 year history of diabetes mellitus was treated with low level antibodies. The subject was treated with antibody therapy by sublingual administration in the form of 1 drop (or dose), 4.times.per day. Each dose contained 8.times.10.sup.-4 mg of anti-GAD and 4.times.10.sup.-4 mg of anti-insulin antibodies. The antibodies used in this example are the same as that used above in Example I. After approximately one week, the subject experienced an abatement of pain from diabetic neuropathy and a reduction in blood sugar levels. Following a one week period in which the subject experiences no pain, the subject was discontinued from low level antibody treatment. The discontinuation resulted in reoccurrence of diabetic neuropathy and elevated blood sugar levels, which were the symptoms experience by the subject prior to low level antibody treatment. Subsequently, the subject was, again, treated with low level antibody therapy, which resulted in abatement of pain from diabetic neuropathy and a reduction in blood sugar levels similar to the result from the initial therapy with low level antibodies.
Example XII
According to this example, a white male diagnosed with diabetes was treated with low level antibodies. The subject was treated with antibody therapy by sublingual administration in the form of 1 drop (or dose), 2.times.per day. Each dose contained 8.times.10.sup.-4 mg of anti-GAD (Ab directed against combination of GAD-65 and GAD-67) and 4.times.10.sup.-4 mg of anti-insulin antibodies. The antibodies used in this example are the same as that used above in Example I. After approximately eight weeks the subject experienced a reduction in diabetic neuropathy of approximately 60%. This reduction in diabetic neuropathy was determined by having the patient assess the sensations resulting from a tuning fork on the subject's lower extremities just prior to treatment and after the eight weeks of treatment. Additionally, the subject experienced a loss in weight (approximately 12 lbs), increased energy and a reduction in levels of blood sugar of about 40 mg/dl.
[ Follow Ups ] [ Post Followup ] [ The Islet Foundation Message Forum ] [ FAQ ]